The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
Open accessAbstract
UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflammatory cholangiopathy. The role of the microbiota in PSC etiopathogenesis may be fundamentally important, yet remains obscure. We tested the hypothesis that germ-free (GF) mutltidrug resistance 2 knockout (mdr2(-/-) ) mice develop a distinct PSC phenotype, compared to conventionally housed (CV) mdr2(-/-) mice. Mdr2(-/-) mice (n = 12) were rederived as GF by embryo transfer, maintained in isolators, and sacrificed at 60 days in parallel with age-matched CV mdr2(-/-) mice. Serum biochemistries, gallbladder bile acids, and liver sections were examined. Histological findings were validated morphometrically, biochemically, and by immunofluorescence microscopy (IFM). Cholangiocyte senescence was assessed by p16(INK4a) in situ hybridization in liver tissue and by senescence-associated β-galactosidase staining in a culture-based model of insult-induced senescence. Serum biochemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were significantly higher in GF mdr2(-/-) (P < 0.01). Primary bile acids were similar, whereas secondary bile acids were absent, in GF mdr2(-/-) mice. Fibrosis, ductular reaction, and ductopenia were significantly more severe histopathologically in GF mdr2(-/-) mice (P < 0.01) and were confirmed by hepatic morphometry, hydroxyproline assay, and IFM. Cholangiocyte senescence was significantly increased in GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment. CONCLUSIONS: GF mdr2(-/-) mice exhibit exacerbated biochemical and histological features of PSC and increased cholangiocyte senescence, a characteristic and potential mediator of progressive biliary disease. UDCA, a commensal microbial metabolite, abrogates senescence in vitro. These findings demonstrate the importance of the commensal microbiota and its metabolites in protecting against biliary injury and suggest avenues for future studies of biomarkers and therapeutic interventions in PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“total elimination of intestinal microbiome in germ-free mice has been shown to aggravate liver injury in mouse models of liver fibrosis and PSC.64 65”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [65]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [76]
In the citing paper
“However, recent studies have demonstrated an increase in liver fibrosis in germ-free mice75,76, which seemingly contradicts the decrease of liver fibrosis seen in gut-sterilized mice.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 1×
“Although still an active area of research, the protective effects of the commensal microbiota can be considered in two broad categories: (1) production of cytoprotective metabolites (or decreased production of injurious metabolites)(40-42) and (2) facilitation of normal immunological development.(42) Fig.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 2×
“With this in mind, it is plausible that an alternative potential explanation for the increased degree of cholangiocyte senescence in GF mdr22/2 mice might be a relative immunological defect in GF mdr22/2 mice resulting in impaired clearance of senescent BECs.49,50 Senescent cell clearance has only recently been explor…”
BackgroundChemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 1×
“, induce senescence in neighboring cells), and initiate profibroinflammatory and protumorigenic cellular responses and outcomes.(43,45,46) Therefore, we propose that the high proportion of senescent cholangiocytes observed in GF mdr2 mice represents both a marker as well as a driver of more severe hepatobiliary diseas…”
BackgroundCellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774 · cited 2×
“Senescent cell clearance has only recently been explored, but may ultimately hold therapeutic promise in PSC (even in more advanced stages of disease) and other disorders.(44) In summary, by generating the first GF variant of the mdr2 murine model of PSC, we have demonstrated that the absence of the commensal microbio…”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function
Olszak, T., An, D., Zeissig, S., Vera, M. P., Richter, J., Franke, A., Glickman, J. N., Siebert, R., Baron, R. M., Kasper, D. L., et al. (2012) · Science · doi:10.1126/science.1219328 · Cited by 1,661
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 2×
“With this in mind, it is plausible that an alternative potential explanation for the increased degree of cholangiocyte senescence in GF mdr22/2 mice might be a relative immunological defect in GF mdr22/2 mice resulting in impaired clearance of senescent BECs.49,50 Senescent cell clearance has only recently been explor…”
BackgroundSmit, J., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van ROON, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,230
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–224 of 224
Future Therapies for Primary Sclerosing Cholangitis
Lammert, C. S., & Vuppalanchi, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_12
Primary Sclerosing Cholangitis (PSC): Current Concepts in Biology and Strategies for New Therapy
Trivedi, P. J., & Karlsen, T. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_9
Cellular Senescence and Biliary Disorders
Sasaki, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-3500-5_4
Jaramillo, C., Valentino, P. L., & Deneau, M. R. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0353-y
The Impact of Gut Microbiota on Liver Injury
Feng, W., & McClain, C. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58106-4_11
Emerging therapeutic targets for primary sclerosing cholangitis
Kalani, A., Tabibian, J. H., & Lindor, K. D. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1490643
“ductopenia, ductular reaction, and advanced fibrosis [74].”
Self-citationNovel insights into the role of bacterial gut microbiota in hepatocellular carcinoma
Chang, R., Zhang, L., Qiu, G., Xu, X., & Zhou, Y. (2018) · Cancer translational medicine · doi:10.4103/ctm.ctm_8_18
Intestinal Microbiome and the Liver
Gillevet, P. M., & Puri, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00003-3
Progress of Intestinal Flora in the Treatment of Autoimmune Liver Disease
石, 莉. (2020) · Traditional Chinese Medicine · doi:10.12677/tcm.2020.94052
Shriki, A., Lanton, T., Sonnenblick, A., Levkovitch‐Siany, O., Eidelshtein, D., Abramovitch, R., Rosenberg, N., Pappo, O., Elgavish, S., Nevo, Y., et al. (2023) · doi:10.1158/0008-5472.c.6512938.v1
Jin, M., Cui, J., 宁慧娟, Wang, M., Liu, W., Yao, K., Yuan, J., & Zhong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26642311
Jin, M., Cui, J., 宁慧娟, Wang, M., Liu, W., Yao, K., Yuan, J., & Zhong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26642308
Сергеевна, С. Е., Vinnitskaya, E. V., & Parfenov, A. I. (2026) · Terapevticheskii arkhiv · doi:10.26442/00403660.2026.02.203529
“В то же время другие авторы подтверждают концепцию, касающуюся защитной роли комменсальной микробиоты и ее метабо-литов в патобиологии повреждения ЖВП и ПСХ [37].”
Dysbiosis in the Gut‐Liver Axis Is Associated With Low Bone Mass During Murine Cholestasis
Hutchison, B., Fornsaglio, J. L., Case, R., IV, Cornuet, P. K., Qin, F., Ma, X., Nejak‐Bowen, K. N., & Carson, M. D. (2026) · The FASEB Journal · doi:10.1096/fj.202502976r
Microbiome-immune interactions in autoimmune liver diseases
Kiseleva, Y. V., Maslennikov, R. V., Poluektova, E. A., Zolnikova, O., Sigidaev, A. S., Zharikov, Y. O., Shirokova, E. N., & Ivashkin, V. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i12.115853 · Cited by 1
Schofield, A., Kamath, B., MacParland, S. A., Trauner, M., Trivedi, P., & Mann, J. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101778 · Cited by 1
Interactions foie-intestin dans la cholangite sclérosante primitive
Kemgang, A. (2019) · theses.fr (ABES) · doi:10.70675/43488c90z3a87z4265z8aeaz1b3e77ed5a3b
Impact du microbiome intestinal sur la cholestérolémie : concepts et applications
Bourgin, M. (2021) · theses.fr (ABES) · doi:10.70675/5ef61a78z31c7z44fazafa1zd4a5749a4aaf
Mariaule, V. (2024) · theses.fr (ABES) · doi:10.70675/1d41e841zf788z4dd7z8784zc26304e24ea1
Wan, Y., Zheng, M., Fu, W., Zhu, H., Li, Y., Lin, H., Chen, J., Li, J., Mo, Q., Tai, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785064
Yan, J., Jiang, L., Li, Y., Lv, H., Wu, W., Yang, L., Chen, J., & Ding, S. (2026) · Microorganisms · doi:10.3390/microorganisms14051076
Hsu, S., Chua, H., Liou, B., Cheng, Y., Lin, C.-R., Chen, Y., Yang, T., Wu, S., Tsuei, D., Chen, H., et al. (2026) · The Journal of Pathology · doi:10.1002/path.70101
“Some commensal microbiota are hepatoprotective in mouse models of liver fi brosis and primary sclerosing cholangitis (PSC) [10,11], whereas others promote liver diseases in mouse models of nonalcoholic fatty liver diseases [12,13] and liver tumor growth [14].”
Crosstalk along the gut–liver axis in liver disease: Clinical and mechanistic aspects
Nakamoto, N., Okada, H., Bäckhed, F., Schnabl, B., & Hov, J. R. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.10.019
Metadata
- Authors
- Tabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F.
- Affiliations
- Mayo Clinic (US)
- Division of Gastroenterology and Hepatology,Mayo Clinic,Rochester,MN
- University of California San Diego (US)
- Corresponding author
- LaRusso, Nicholas F.
- Venue
- Hepatology
- Published
- 2015-08-10
- Volume
- 63
- Issue
- 1
- Pages
- 185-196
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC4670294
- OpenAlex
- W1945590693
- Cited by
- 223
- References
- 50
- Citations by year
- 2026: 14 · 2025: 7 · 2024: 17 · 2023: 18 · 2022: 17 · 2021: 24 · 2020: 20 · 2019: 25 · 2018: 27 · 2017: 28 · 2016: 19 · 2015: 5
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic (P30 DK084567)
- Mayo Foundation for Medical Education and Research
- PSC Partners Seeking a Cure
- National Institutes of Health
- University of California, San Diego
- Center for Cell Signaling in Gastroenterology, Mayo Clinic (P30 DK084567)
- National Institute of Allergy and Infectious Diseases (R01AI089713, AI089713)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57993, P30DK084567, R01DK057993)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary sclerosing cholangitis, gut microbiota, germ-free mice, Mdr2 knockout mice, bile acid metabolism, secondary bile acids, ursodeoxycholic acid, liver fibrosis, ductopenia, biliary injury
- MeSH terms
- Gastrointestinal Microbiome, Animals, Disease Models, Animal, Female, Male, Cholangitis, Sclerosing, Mice, Knockout, Disease Progression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
